Emerging bispecific antibodies and CAR T cell therapies show promising advances across multiple cancer types. Regeneron’s FDA approval of Lynozyfic for multiple myeloma provides dosing flexibility distinct from competitors, while dual immune checkpoint blockade targeting TIGIT and PD-1 reveals efficacy in liver cancer. Engineered CAR T cells employing endogenous promoters to regulate immunomodulatory cytokines improve tumor targeting, and a novel “leukemia-on-a-chip” model accelerates screening for CAR T therapies. Additionally, CAR T applications are progressing against Claudin18.2-positive gastric cancers with regulatory bodies reviewing new drug applications, signaling a broad expansion in immuno-oncology modalities.